Drugs / Tocetaxel
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT06138028 | Sep 2023 → Oct 2025 overdue | esophageal squamous cell carcinoma | Qingdao Central Hospital | Recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Tocetaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06138028 ↗ |